Global Anti-Obesity Prescription Drugs Market Growth 2020-2025

Publication Month: Nov 2020 | No. of Pages: 133 Published By: LP Information
Single User License: US $ 3660
Corporate User License: US $ 7320

According to this study, over the next five years the Anti-Obesity Prescription Drugs market will register a 5.2%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Anti-Obesity Prescription Drugs business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Anti-Obesity Prescription Drugs market by product type, application, key manufacturers and key regions and countries.

This study specially analyses the impact of Covid-19 outbreak on the Anti-Obesity Prescription Drugs, covering the supply chain analysis, impact assessment to the Anti-Obesity Prescription Drugs market size growth rate in several scenarios, and the measures to be undertaken by Anti-Obesity Prescription Drugs companies in response to the COVID-19 epidemic.

Segmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7.
Pediatric
Adult

Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8.
Hospitals Pharmacies
Retail Pharmacies
E-commerce

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
F Hoffmann La Roche Ltd
Orexigen Therapeutics
Arena Pharmaceuticals
Glaxosmithkline
Novo Nordisk A/s
Alizyme
Vivus
Boehringer Ingelheim

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Anti-Obesity Prescription Drugs consumption (value & volume) by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
To understand the structure of Anti-Obesity Prescription Drugs market by identifying its various subsegments.
Focuses on the key global Anti-Obesity Prescription Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Anti-Obesity Prescription Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Anti-Obesity Prescription Drugs submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Data Source
1.6 Economic Indicators
1.7 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Anti-Obesity Prescription Drugs Consumption 2015-2025
2.1.2 Anti-Obesity Prescription Drugs Consumption CAGR by Region
2.2 Anti-Obesity Prescription Drugs Segment by Type
2.2.1 Pediatric
2.2.2 Adult
2.3 Anti-Obesity Prescription Drugs Consumption by Type
2.3.1 Global Anti-Obesity Prescription Drugs Consumption Market Share by Type (2015-2020)
2.3.2 Global Anti-Obesity Prescription Drugs Revenue and Market Share by Type (2015-2020)
2.3.3 Global Anti-Obesity Prescription Drugs Sale Price by Type (2015-2020)
2.4 Anti-Obesity Prescription Drugs Segment by Application
2.4.1 Hospitals Pharmacies
2.4.2 Retail Pharmacies
2.4.3 E-commerce
2.5 Anti-Obesity Prescription Drugs Consumption by Application
2.5.1 Global Anti-Obesity Prescription Drugs Consumption Market Share by Type (2015-2020)
2.5.2 Global Anti-Obesity Prescription Drugs Value and Market Share by Type (2015-2020)
2.5.3 Global Anti-Obesity Prescription Drugs Sale Price by Type (2015-2020)

3 Global Anti-Obesity Prescription Drugs by Company
3.1 Global Anti-Obesity Prescription Drugs Sales Market Share by Company
3.1.1 Global Anti-Obesity Prescription Drugs Sales by Company (2018-2020)
3.1.2 Global Anti-Obesity Prescription Drugs Sales Market Share by Company (2018-2020)
3.2 Global Anti-Obesity Prescription Drugs Revenue Market Share by Company
3.2.1 Global Anti-Obesity Prescription Drugs Revenue by Company (2018-2020)
3.2.2 Global Anti-Obesity Prescription Drugs Revenue Market Share by Company (2018-2020)
3.3 Global Anti-Obesity Prescription Drugs Sale Price by Company
3.4 Global Anti-Obesity Prescription Drugs Manufacturing Base Distribution, Sales Area, Type by Company
3.4.1 Global Anti-Obesity Prescription Drugs Manufacturing Base Distribution and Sales Area by Company
3.4.2 Players Anti-Obesity Prescription Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 Anti-Obesity Prescription Drugs by Regions
4.1 Anti-Obesity Prescription Drugs by Regions
4.2 Americas Anti-Obesity Prescription Drugs Consumption Growth
4.3 APAC Anti-Obesity Prescription Drugs Consumption Growth
4.4 Europe Anti-Obesity Prescription Drugs Consumption Growth
4.5 Middle East & Africa Anti-Obesity Prescription Drugs Consumption Growth

5 Americas
5.1 Americas Anti-Obesity Prescription Drugs Consumption by Countries
5.1.1 Americas Anti-Obesity Prescription Drugs Consumption by Countries (2015-2020)
5.1.2 Americas Anti-Obesity Prescription Drugs Value by Countries (2015-2020)
5.2 Americas Anti-Obesity Prescription Drugs Consumption by Type
5.3 Americas Anti-Obesity Prescription Drugs Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
5.8 Key Economic Indicators of Few Americas Countries

6 APAC
6.1 APAC Anti-Obesity Prescription Drugs Consumption by Regions
6.1.1 APAC Anti-Obesity Prescription Drugs Consumption by Regions (2015-2020)
6.1.2 APAC Anti-Obesity Prescription Drugs Value by Regions (2015-2020)
6.2 APAC Anti-Obesity Prescription Drugs Consumption by Type
6.3 APAC Anti-Obesity Prescription Drugs Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions

7 Europe
7.1 Europe Anti-Obesity Prescription Drugs by Countries
7.1.1 Europe Anti-Obesity Prescription Drugs Consumption by Countries (2015-2020)
7.1.2 Europe Anti-Obesity Prescription Drugs Value by Countries (2015-2020)
7.2 Europe Anti-Obesity Prescription Drugs Consumption by Type
7.3 Europe Anti-Obesity Prescription Drugs Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa
8.1 Middle East & Africa Anti-Obesity Prescription Drugs by Countries
8.1.1 Middle East & Africa Anti-Obesity Prescription Drugs Consumption by Countries (2015-2020)
8.1.2 Middle East & Africa Anti-Obesity Prescription Drugs Value by Countries (2015-2020)
8.2 Middle East & Africa Anti-Obesity Prescription Drugs Consumption by Type
8.3 Middle East & Africa Anti-Obesity Prescription Drugs Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Anti-Obesity Prescription Drugs Distributors
10.3 Anti-Obesity Prescription Drugs Customer

11 Global Anti-Obesity Prescription Drugs Market Forecast
11.1 Global Anti-Obesity Prescription Drugs Consumption Forecast (2021-2025)
11.2 Global Anti-Obesity Prescription Drugs Forecast by Regions
11.2.1 Global Anti-Obesity Prescription Drugs Forecast by Regions (2021-2025)
11.2.2 Global Anti-Obesity Prescription Drugs Value Forecast by Regions (2021-2025)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast byRegions
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Anti-Obesity Prescription Drugs Forecast by Type
11.8 Global Anti-Obesity Prescription Drugs Forecast by Application

12 Key Players Analysis
12.1 F Hoffmann La Roche Ltd
12.1.1 Company Information
12.1.2 Anti-Obesity Prescription Drugs Product Offered
12.1.3 F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.1.4 Main Business Overview
12.1.5 F Hoffmann La Roche Ltd Latest Developments
12.2 Orexigen Therapeutics
12.2.1 Company Information
12.2.2 Anti-Obesity Prescription Drugs Product Offered
12.2.3 Orexigen Therapeutics Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.2.4 Main Business Overview
12.2.5 Orexigen Therapeutics Latest Developments
12.3 Arena Pharmaceuticals
12.3.1 Company Information
12.3.2 Anti-Obesity Prescription Drugs Product Offered
12.3.3 Arena Pharmaceuticals Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.3.4 Main Business Overview
12.3.5 Arena Pharmaceuticals Latest Developments
12.4 Glaxosmithkline
12.4.1 Company Information
12.4.2 Anti-Obesity Prescription Drugs Product Offered
12.4.3 Glaxosmithkline Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.4.4 Main Business Overview
12.4.5 Glaxosmithkline Latest Developments
12.5 Novo Nordisk A/s
12.5.1 Company Information
12.5.2 Anti-Obesity Prescription Drugs Product Offered
12.5.3 Novo Nordisk A/s Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.5.4 Main Business Overview
12.5.5 Novo Nordisk A/s Latest Developments
12.6 Alizyme
12.6.1 Company Information
12.6.2 Anti-Obesity Prescription Drugs Product Offered
12.6.3 Alizyme Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.6.4 Main Business Overview
12.6.5 Alizyme Latest Developments
12.7 Vivus
12.7.1 Company Information
12.7.2 Anti-Obesity Prescription Drugs Product Offered
12.7.3 Vivus Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.7.4 Main Business Overview
12.7.5 Vivus Latest Developments
12.8 Boehringer Ingelheim
12.8.1 Company Information
12.8.2 Anti-Obesity Prescription Drugs Product Offered
12.8.3 Boehringer Ingelheim Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.8.4 Main Business Overview
12.8.5 Boehringer Ingelheim Latest Developments

13 Research Findings and Conclusion

Tables and Figures

List of Tables
Table 1. Research Methodology
Table 2. Data Source
Table 3. Anti-Obesity Prescription Drugs Consumption CAGR by Region 2015-2025 ($ Millions)
Table 4. Major Players of Pediatric
Table 5. Major Players of Adult
Table 6. Global Consumption Sales by Type (2015-2020)
Table 7. Global Anti-Obesity Prescription Drugs Consumption Market Share by Type (2015-2020)
Table 8. Global Anti-Obesity Prescription Drugs Revenue by Type (2015-2020) ($ million)
Table 9. Global Anti-Obesity Prescription Drugs Value Market Share by Type (2015-2020) ($ Millions)
Table 10. Global Anti-Obesity Prescription Drugs Sale Price by Type (2015-2020)
Table 11. Global Consumption Sales by Application (2015-2020)
Table 12. Global Anti-Obesity Prescription Drugs Consumption Market Share by Application (2015-2020)
Table 13. Global Anti-Obesity Prescription Drugs Value by Application (2015-2020)
Table 14. Global Anti-Obesity Prescription Drugs Value Market Share by Application (2015-2020)
Table 15. Global Anti-Obesity Prescription Drugs Sale Price by Application (2015-2020)
Table 16. Global Anti-Obesity Prescription Drugs Sales by Company (2017-2019) (K Units)
Table 17. Global Anti-Obesity Prescription Drugs Sales Market Share by Company (2017-2019)
Table 18. Global Anti-Obesity Prescription Drugs Revenue by Company (2017-2019) ($ Millions)
Table 19. Global Anti-Obesity Prescription Drugs Revenue Market Share by Company (2017-2019)
Table 20. Global Anti-Obesity Prescription Drugs Sale Price by Company (2017-2019)
Table 21. Global Anti-Obesity Prescription Drugs Manufacturing Base Distribution and Sales Area by Manufacturers
Table 22. Players Anti-Obesity Prescription Drugs Products Offered
Table 23. Anti-Obesity Prescription Drugs Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
Table 24. Global Anti-Obesity Prescription Drugs Consumption by Regions 2015-2020 (K Units)
Table 25. Global Anti-Obesity Prescription Drugs Consumption Market Share by Regions 2015-2020
Table 26. Global Anti-Obesity Prescription Drugs Value by Regions 2015-2020 ($ Millions)
Table 27. Global Anti-Obesity Prescription Drugs Value Market Share by Regions 2015-2020
Table 28. Americas Anti-Obesity Prescription Drugs Consumption by Countries (2015-2020) (K Units)
Table 29. Americas Anti-Obesity Prescription Drugs Consumption Market Share by Countries (2015-2020)
Table 30. Americas Anti-Obesity Prescription Drugs Value by Countries (2015-2020) ($ Millions)
Table 31. Americas Anti-Obesity Prescription Drugs Value Market Share by Countries (2015-2020)
Table 32. Americas Anti-Obesity Prescription Drugs Consumption by Type (2015-2020) (K Units)
Table 33. Americas Anti-Obesity Prescription Drugs Consumption Market Share by Type (2015-2020)
Table 34. Americas Anti-Obesity Prescription Drugs Consumption by Application (2015-2020) (K Units)
Table 35. Americas Anti-Obesity Prescription Drugs Consumption Market Share by Application (2015-2020)
Table 36. APAC Anti-Obesity Prescription Drugs Consumption by Regions (2015-2020) (K Units)
Table 37. APAC Anti-Obesity Prescription Drugs Consumption Market Share by Regions (2015-2020)
Table 38. APAC Anti-Obesity Prescription Drugs Value by Regions (2015-2020) ($ Millions)
Table 39. APAC Anti-Obesity Prescription Drugs Value Market Share by Regions (2015-2020)
Table 40. APAC Anti-Obesity Prescription Drugs Consumption by Type (2015-2020) (K Units)
Table 41. APAC Anti-Obesity Prescription Drugs Consumption Market Share by Type (2015-2020)
Table 42. APAC Anti-Obesity Prescription Drugs Consumption by Application (2015-2020) (K Units)
Table 43. APAC Anti-Obesity Prescription Drugs Consumption Market Share by Application (2015-2020)
Table 44. Europe Anti-Obesity Prescription Drugs Consumption by Countries (2015-2020) (K Units)
Table 45. Europe Anti-Obesity Prescription Drugs Consumption Market Share by Countries (2015-2020)
Table 46. Europe Anti-Obesity Prescription Drugs Value by Countries (2015-2020) ($ Millions)
Table 47. Europe Anti-Obesity Prescription Drugs Value Market Share by Countries (2015-2020)
Table 48. Europe Anti-Obesity Prescription Drugs Consumption by Type (2015-2020) (K Units)
Table 49. Europe Anti-Obesity Prescription Drugs Consumption Market Share by Type (2015-2020)
Table 50. Europe Anti-Obesity Prescription Drugs Consumption by Application (2015-2020) (K Units)
Table 51. Europe Anti-Obesity Prescription Drugs Consumption Market Share by Application (2015-2020)
Table 52. Middle East & Africa Anti-Obesity Prescription Drugs Consumption by Countries (2015-2020) (K Units)
Table 53. Middle East & Africa Anti-Obesity Prescription Drugs Consumption Market Share by Countries (2015-2020)
Table 54. Middle East & Africa Anti-Obesity Prescription Drugs Value by Countries (2015-2020) ($ Millions)
Table 55. Middle East & Africa Anti-Obesity Prescription Drugs Value Market Share by Countries (2015-2020)
Table 56. Middle East & Africa Anti-Obesity Prescription Drugs Consumption by Type (2015-2020) (K Units)
Table 57. Middle East & Africa Anti-Obesity Prescription Drugs Consumption Market Share by Type (2015-2020)
Table 58. Middle East & Africa Anti-Obesity Prescription Drugs Consumption by Application (2015-2020) (K Units)
Table 59. Middle East & Africa Anti-Obesity Prescription Drugs Consumption Market Share by Application (2015-2020)
Table 60. Anti-Obesity Prescription Drugs Distributors List
Table 61. Anti-Obesity Prescription Drugs Customer List
Table 62. Global Anti-Obesity Prescription Drugs Consumption Forecast by Countries (2021-2025) (K Units)
Table 63. Global Anti-Obesity Prescription Drugs Consumption Market Forecast by Regions
Table 64. Global Anti-Obesity Prescription Drugs Value Forecast by Countries (2021-2025) ($ Millions)
Table 65. Global Anti-Obesity Prescription Drugs Value Market Share Forecast by Regions
Table 66. Global Anti-Obesity Prescription Drugs Consumption Forecast by Type (2021-2025) (K Units)
Table 67. Global Anti-Obesity Prescription Drugs Consumption Market Share Forecast by Type (2021-2025)
Table 68. Global Anti-Obesity Prescription Drugs Value Forecast by Type (2021-2025) ($ Millions)
Table 69. Global Anti-Obesity Prescription Drugs Value Market Share Forecast by Type (2021-2025)
Table 70. Global Anti-Obesity Prescription Drugs Consumption Forecast by Application (2021-2025) (K Units)
Table 71. Global Anti-Obesity Prescription Drugs Consumption Market Share Forecast by Application (2021-2025)
Table 72. Global Anti-Obesity Prescription Drugs Value Forecast by Application (2021-2025) ($ Millions)
Table 73. Global Anti-Obesity Prescription Drugs Value Market Share Forecast by Application (2021-2025)
Table 74. F Hoffmann La Roche Ltd Product Offered
Table 75. F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 76. F Hoffmann La Roche Ltd Main Business
Table 77. F Hoffmann La Roche Ltd Latest Developments
Table 78. F Hoffmann La Roche Ltd Basic Information, Company Total Revenue (in $ million), Anti-Obesity Prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 79. Orexigen Therapeutics Product Offered
Table 80. Orexigen Therapeutics Anti-Obesity Prescription Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 81. Orexigen Therapeutics Main Business
Table 82. Orexigen Therapeutics Latest Developments
Table 83. Orexigen Therapeutics Basic Information, Company Total Revenue (in $ million), Anti-Obesity Prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 84. Arena Pharmaceuticals Product Offered
Table 85. Arena Pharmaceuticals Anti-Obesity Prescription Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 86. Arena Pharmaceuticals Main Business
Table 87. Arena Pharmaceuticals Latest Developments
Table 88. Arena Pharmaceuticals Basic Information, Company Total Revenue (in $ million), Anti-Obesity Prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 89. Glaxosmithkline Product Offered
Table 90. Glaxosmithkline Anti-Obesity Prescription Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 91. Glaxosmithkline Main Business
Table 92. Glaxosmithkline Latest Developments
Table 93. Glaxosmithkline Basic Information, Company Total Revenue (in $ million), Anti-Obesity Prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 94. Novo Nordisk A/s Product Offered
Table 95. Novo Nordisk A/s Anti-Obesity Prescription Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 96. Novo Nordisk A/s Main Business
Table 97. Novo Nordisk A/s Latest Developments
Table 98. Novo Nordisk A/s Basic Information, Company Total Revenue (in $ million), Anti-Obesity Prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 99. Alizyme Product Offered
Table 100. Alizyme Anti-Obesity Prescription Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 101. Alizyme Main Business
Table 102. Alizyme Latest Developments
Table 103. Alizyme Basic Information, Company Total Revenue (in $ million), Anti-Obesity Prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 104. Vivus Product Offered
Table 105. Vivus Basic Information, Company Total Revenue (in $ million), Anti-Obesity Prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 106. Vivus Main Business
Table 107. Vivus Latest Developments
Table 108. Vivus Anti-Obesity Prescription Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 109. Boehringer Ingelheim Product Offered
Table 110. Boehringer Ingelheim Anti-Obesity Prescription Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 111. Boehringer Ingelheim Main Business
Table 112. Boehringer Ingelheim Latest Developments
Table 113. Boehringer Ingelheim Basic Information, Company Total Revenue (in $ million), Anti-Obesity Prescription Drugs Manufacturing Base, Sales Area and Its Competitors
List of Figures
Figure 1. Picture of Anti-Obesity Prescription Drugs
Figure 2. Anti-Obesity Prescription Drugs Report Years Considered
Figure 3. Market Research Methodology
Figure 4. Global Anti-Obesity Prescription Drugs Consumption Growth Rate 2015-2025 (K Units)
Figure 5. Global Anti-Obesity Prescription Drugs Value Growth Rate 2015-2025 ($ Millions)
Figure 6. Product Picture of Pediatric
Figure 7. Product Picture of Adult
Figure 8. Global Anti-Obesity Prescription Drugs Consumption Market Share by Type (2015-2020)
Figure 9. Global Anti-Obesity Prescription Drugs Value Market Share by Type (2015-2020)
Figure 10. Anti-Obesity Prescription Drugs Consumed in Hospitals Pharmacies
Figure 11. Global Anti-Obesity Prescription Drugs Market: Hospitals Pharmacies (2015-2020) (K Units)
Figure 12. Global Anti-Obesity Prescription Drugs Market: Hospitals Pharmacies (2015-2020) ($ Millions)
Figure 13. Anti-Obesity Prescription Drugs Consumed in Retail Pharmacies
Figure 14. Global Anti-Obesity Prescription Drugs Market: Retail Pharmacies (2015-2020) (K Units)
Figure 15. Global Anti-Obesity Prescription Drugs Market: Retail Pharmacies (2015-2020) ($ Millions)
Figure 16. Anti-Obesity Prescription Drugs Consumed in E-commerce
Figure 17. Global Anti-Obesity Prescription Drugs Market: E-commerce (2015-2020) (K Units)
Figure 18. Global Anti-Obesity Prescription Drugs Market: E-commerce (2015-2020) ($ Millions)
Figure 19. Global Anti-Obesity Prescription Drugs Consumption Market Share by Application (2015-2020)
Figure 20. Global Anti-Obesity Prescription Drugs Value Market Share by Application (2015-2020)
Figure 21. Global Anti-Obesity Prescription Drugs Sales Market Share by Company in 2017
Figure 22. Global Anti-Obesity Prescription Drugs Sales Market Share by Company in 2019
Figure 23. Global Anti-Obesity Prescription Drugs Revenue Market Share by Company in 2017
Figure 24. Global Anti-Obesity Prescription Drugs Revenue Market Share by Company in 2019
Figure 25. Global Anti-Obesity Prescription Drugs Sale Price by Company in 2019
Figure 26. Global Anti-Obesity Prescription Drugs Consumption Market Share by Regions 2015-2020
Figure 27. Global Anti-Obesity Prescription Drugs Value Market Share by Regions 2015-2020
Figure 28. Americas Anti-Obesity Prescription Drugs Consumption 2015-2020 (K Units)
Figure 29. Americas Anti-Obesity Prescription Drugs Value 2015-2020 ($ Millions)
Figure 30. APAC Anti-Obesity Prescription Drugs Consumption 2015-2020 (K Units)
Figure 31. APAC Anti-Obesity Prescription Drugs Value 2015-2020 ($ Millions)
Figure 32. Europe Anti-Obesity Prescription Drugs Consumption 2015-2020 (K Units)
Figure 33. Europe Anti-Obesity Prescription Drugs Value 2015-2020 ($ Millions)
Figure 34. Middle East & Africa Anti-Obesity Prescription Drugs Consumption 2015-2020 (K Units)
Figure 35. Middle East & Africa Anti-Obesity Prescription Drugs Value 2015-2020 ($ Millions)
Figure 36. Americas Anti-Obesity Prescription Drugs Consumption Market Share by Countries in 2019
Figure 37. Americas Anti-Obesity Prescription Drugs Value Market Share by Countries in 2019
Figure 38. Americas Anti-Obesity Prescription Drugs Consumption Market Share by Type in 2019
Figure 39. Americas Anti-Obesity Prescription Drugs Consumption Market Share by Application in 2019
Figure 40. United States Anti-Obesity Prescription Drugs Consumption Growth 2015-2020 (K Units)
Figure 41. United States Anti-Obesity Prescription Drugs Value Growth 2015-2020 ($ Millions)
Figure 42. Canada Anti-Obesity Prescription Drugs Consumption Growth 2015-2020 (K Units)
Figure 43. Canada Anti-Obesity Prescription Drugs Value Growth 2015-2020 ($ Millions)
Figure 44. Mexico Anti-Obesity Prescription Drugs Consumption Growth 2015-2020 (K Units)
Figure 45. Mexico Anti-Obesity Prescription Drugs Value Growth 2015-2020 ($ Millions)
Figure 46. APAC Anti-Obesity Prescription Drugs Consumption Market Share by Countries in 2019
Figure 47. APAC Anti-Obesity Prescription Drugs Value Market Share by Regions in 2019
Figure 48. APAC Anti-Obesity Prescription Drugs Consumption Market Share by Type in 2019
Figure 49. APAC Anti-Obesity Prescription Drugs Consumption Market Share by Application in 2019
Figure 50. China Anti-Obesity Prescription Drugs Consumption Growth 2015-2020 (K Units)
Figure 51. China Anti-Obesity Prescription Drugs Value Growth 2015-2020 ($ Millions)
Figure 52. Japan Anti-Obesity Prescription Drugs Consumption Growth 2015-2020 (K Units)
Figure 53. Japan Anti-Obesity Prescription Drugs Value Growth 2015-2020 ($ Millions)
Figure 54. Korea Anti-Obesity Prescription Drugs Consumption Growth 2015-2020 (K Units)
Figure 55. Korea Anti-Obesity Prescription Drugs Value Growth 2015-2020 ($ Millions)
Figure 56. Southeast Asia Anti-Obesity Prescription Drugs Consumption Growth 2015-2020 (K Units)
Figure 57. Southeast Asia Anti-Obesity Prescription Drugs Value Growth 2015-2020 ($ Millions)
Figure 58. India Anti-Obesity Prescription Drugs Consumption Growth 2015-2020 (K Units)
Figure 59. India Anti-Obesity Prescription Drugs Value Growth 2015-2020 ($ Millions)
Figure 60. Australia Anti-Obesity Prescription Drugs Consumption Growth 2015-2020 (K Units)
Figure 61. Australia Anti-Obesity Prescription Drugs Value Growth 2015-2020 ($ Millions)
Figure 62. Europe Anti-Obesity Prescription Drugs Consumption Market Share by Countries in 2019
Figure 63. Europe Anti-Obesity Prescription Drugs Value Market Share by Countries in 2019
Figure 64. Europe Anti-Obesity Prescription Drugs Consumption Market Share by Type in 2019
Figure 65. Europe Anti-Obesity Prescription Drugs Consumption Market Share by Application in 2019
Figure 66. Germany Anti-Obesity Prescription Drugs Consumption Growth 2015-2020 (K Units)
Figure 67. Germany Anti-Obesity Prescription Drugs Value Growth 2015-2020 ($ Millions)
Figure 68. France Anti-Obesity Prescription Drugs Consumption Growth 2015-2020 (K Units)
Figure 69. France Anti-Obesity Prescription Drugs Value Growth 2015-2020 ($ Millions)
Figure 70. UK Anti-Obesity Prescription Drugs Consumption Growth 2015-2020 (K Units)
Figure 71. UK Anti-Obesity Prescription Drugs Value Growth 2015-2020 ($ Millions)
Figure 72. Italy Anti-Obesity Prescription Drugs Consumption Growth 2015-2020 (K Units)
Figure 73. Italy Anti-Obesity Prescription Drugs Value Growth 2015-2020 ($ Millions)
Figure 74. Russia Anti-Obesity Prescription Drugs Consumption Growth 2015-2020 (K Units)
Figure 75. Russia Anti-Obesity Prescription Drugs Value Growth 2015-2020 ($ Millions)
Figure 76. Middle East & Africa Anti-Obesity Prescription Drugs Consumption Market Share by Countries in 2019
Figure 77. Middle East & Africa Anti-Obesity Prescription Drugs Value Market Share by Countries in 2019
Figure 78. Middle East & Africa Anti-Obesity Prescription Drugs Consumption Market Share by Type in 2019
Figure 79. Middle East & Africa Anti-Obesity Prescription Drugs Consumption Market Share by Application in 2019
Figure 80. Egypt Anti-Obesity Prescription Drugs Consumption Growth 2015-2020 (K Units)
Figure 81. Egypt Anti-Obesity Prescription Drugs Value Growth 2015-2020 ($ Millions)
Figure 82. South Africa Anti-Obesity Prescription Drugs Consumption Growth 2015-2020 (K Units)
Figure 83. South Africa Anti-Obesity Prescription Drugs Value Growth 2015-2020 ($ Millions)
Figure 84. Israel Anti-Obesity Prescription Drugs Consumption Growth 2015-2020 (K Units)
Figure 85. Israel Anti-Obesity Prescription Drugs Value Growth 2015-2020 ($ Millions)
Figure 86. Turkey Anti-Obesity Prescription Drugs Consumption Growth 2015-2020 (K Units)
Figure 87. Turkey Anti-Obesity Prescription Drugs Value Growth 2015-2020 ($ Millions)
Figure 88. GCC Countries Anti-Obesity Prescription Drugs Consumption Growth 2015-2020 (K Units)
Figure 89. GCC Countries Anti-Obesity Prescription Drugs Value Growth 2015-2020 ($ Millions)
Figure 90. Global Anti-Obesity Prescription Drugs Consumption Growth Rate Forecast (2021-2025) (K Units)
Figure 91. Global Anti-Obesity Prescription Drugs Value Growth Rate Forecast (2021-2025) ($ Millions)
Figure 92. Americas Anti-Obesity Prescription Drugs Consumption 2021-2025 (K Units)
Figure 93. Americas Anti-Obesity Prescription Drugs Value 2021-2025 ($ Millions)
Figure 94. APAC Anti-Obesity Prescription Drugs Consumption 2021-2025 (K Units)
Figure 95. APAC Anti-Obesity Prescription Drugs Value 2021-2025 ($ Millions)
Figure 96. Europe Anti-Obesity Prescription Drugs Consumption 2021-2025 (K Units)
Figure 97. Europe Anti-Obesity Prescription Drugs Value 2021-2025 ($ Millions)
Figure 98. Middle East & Africa Anti-Obesity Prescription Drugs Consumption 2021-2025 (K Units)
Figure 99. Middle East & Africa Anti-Obesity Prescription Drugs Value 2021-2025 ($ Millions)
Figure 100. United States Anti-Obesity Prescription Drugs Consumption 2021-2025 (K Units)
Figure 101. United States Anti-Obesity Prescription Drugs Value 2021-2025 ($ Millions)
Figure 102. Canada Anti-Obesity Prescription Drugs Consumption 2021-2025 (K Units)
Figure 103. Canada Anti-Obesity Prescription Drugs Value 2021-2025 ($ Millions)
Figure 104. Mexico Anti-Obesity Prescription Drugs Consumption 2021-2025 (K Units)
Figure 105. Mexico Anti-Obesity Prescription Drugs Value 2021-2025 ($ Millions)
Figure 106. Brazil Anti-Obesity Prescription Drugs Consumption 2021-2025 (K Units)
Figure 107. Brazil Anti-Obesity Prescription Drugs Value 2021-2025 ($ Millions)
Figure 108. China Anti-Obesity Prescription Drugs Consumption 2021-2025 (K Units)
Figure 109. China Anti-Obesity Prescription Drugs Value 2021-2025 ($ Millions)
Figure 110. Japan Anti-Obesity Prescription Drugs Consumption 2021-2025 (K Units)
Figure 111. Japan Anti-Obesity Prescription Drugs Value 2021-2025 ($ Millions)
Figure 112. Korea Anti-Obesity Prescription Drugs Consumption 2021-2025 (K Units)
Figure 113. Korea Anti-Obesity Prescription Drugs Value 2021-2025 ($ Millions)
Figure 114. Southeast Asia Anti-Obesity Prescription Drugs Consumption 2021-2025 (K Units)
Figure 115. Southeast Asia Anti-Obesity Prescription Drugs Value 2021-2025 ($ Millions)
Figure 116. India Anti-Obesity Prescription Drugs Consumption 2021-2025 (K Units)
Figure 117. India Anti-Obesity Prescription Drugs Value 2021-2025 ($ Millions)
Figure 118. Australia Anti-Obesity Prescription Drugs Consumption 2021-2025 (K Units)
Figure 119. Australia Anti-Obesity Prescription Drugs Value 2021-2025 ($ Millions)
Figure 120. Germany Anti-Obesity Prescription Drugs Consumption 2021-2025 (K Units)
Figure 121. Germany Anti-Obesity Prescription Drugs Value 2021-2025 ($ Millions)
Figure 122. France Anti-Obesity Prescription Drugs Consumption 2021-2025 (K Units)
Figure 123. France Anti-Obesity Prescription Drugs Value 2021-2025 ($ Millions)
Figure 124. UK Anti-Obesity Prescription Drugs Consumption 2021-2025 (K Units)
Figure 125. UK Anti-Obesity Prescription Drugs Value 2021-2025 ($ Millions)
Figure 126. Italy Anti-Obesity Prescription Drugs Consumption 2021-2025 (K Units)
Figure 127. Italy Anti-Obesity Prescription Drugs Value 2021-2025 ($ Millions)
Figure 128. Russia Anti-Obesity Prescription Drugs Consumption 2021-2025 (K Units)
Figure 129. Russia Anti-Obesity Prescription Drugs Value 2021-2025 ($ Millions)
Figure 130. Spain Anti-Obesity Prescription Drugs Consumption 2021-2025 (K Units)
Figure 131. Spain Anti-Obesity Prescription Drugs Value 2021-2025 ($ Millions)
Figure 132. Egypt Anti-Obesity Prescription Drugs Consumption 2021-2025 (K Units)
Figure 133. Egypt Anti-Obesity Prescription Drugs Value 2021-2025 ($ Millions)
Figure 134. South Africa Anti-Obesity Prescription Drugs Consumption 2021-2025 (K Units)
Figure 135. South Africa Anti-Obesity Prescription Drugs Value 2021-2025 ($ Millions)
Figure 136. Israel Anti-Obesity Prescription Drugs Consumption 2021-2025 (K Units)
Figure 137. Israel Anti-Obesity Prescription Drugs Value 2021-2025 ($ Millions)
Figure 138. Turkey Anti-Obesity Prescription Drugs Consumption 2021-2025 (K Units)
Figure 139. Turkey Anti-Obesity Prescription Drugs Value 2021-2025 ($ Millions)
Figure 140. GCC Countries Anti-Obesity Prescription Drugs Consumption 2021-2025 (K Units)
Figure 141. GCC Countries Anti-Obesity Prescription Drugs Value 2021-2025 ($ Millions)
Figure 142. F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Market Share (2018-2020)
Figure 143. Orexigen Therapeutics Anti-Obesity Prescription Drugs Market Share (2018-2020)
Figure 144. Arena Pharmaceuticals Anti-Obesity Prescription Drugs Market Share (2018-2020)
Figure 145. Glaxosmithkline Anti-Obesity Prescription Drugs Market Share (2018-2020)
Figure 146. Novo Nordisk A/s Anti-Obesity Prescription Drugs Market Share (2018-2020)
Figure 147. Alizyme Anti-Obesity Prescription Drugs Market Share (2018-2020)
Figure 148. Vivus Anti-Obesity Prescription Drugs Market Share (2018-2020)
Figure 149. Boehringer Ingelheim Anti-Obesity Prescription Drugs Market Share (2018-2020)


Reason to Buy

  • Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
  • Highlights key business priorities in order to assist companies to realign their business strategies
  • The segment that is expected to dominate the Pharma & Healthcare Market
  • Regions that are expected to witness the fastest growth during the forecast period
  • Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets